RNA Formulation Videos

31. Unlocking The Next Wave Of Cancer Vaccines 4/21/2026

    Discover how advanced ionizable LNP formulations and scalable manufacturing strategies can accelerate the development and clinical translation of personalized cancer vaccines.

32. Polysarcosine-Functionalized LNPs For Therapeutic mRNA Delivery 4/14/2022

    Discover how polysarcosine-functionalized lipid nanoparticles are transforming mRNA delivery. Join Dr. Heinrich Haas of BioNTech as he unveils innovative research and its implications for therapeutic breakthroughs.

33. How To Manufacture LNPs On The Nova Benchtop System 4/18/2024

    Walk step-by-step instructions through how you can set up the Nova Benchtop System and make your first LNPs.

34. Achieving mRNA-LNP Delivery Beyond The Liver 11/28/2022

    In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, discuss which ongoing industry efforts to improve LNPs and the RNA/mRNA cargo they're watching closely that could help the RNA industry move beyond hepatic delivery.

35. How To Successfully Control The Upscaling Of Your LNP Formulation 5/28/2025

    Discover key strategies for controlling LNP formulation and upscaling. Explore the science behind lipid nanoparticles, critical parameters, and achieving effective turbulent mixing for optimal outcomes.

36. The State of the Linear mRNA Supply Chain—In Brief

    In this clip, Sanofi’s Greg Troiano kickstarts our discussion on some of the advances he’s seen in the supply chain for linear mRNA-LNP products, both in terms of supply availability and supplier capability.

37. Software For Liquid Nanoparticle (LNP) Systems 12/6/2024

    Optimize your LNP research with KNAUER's innovative software. Streamline your workflow, overcome challenges, and achieve optimal results with ease.

38. A Wishlist For The Future: The Next Frontier Of The mRNA & Oligo Supply Chains 12/3/2025

    Here, Advancing RNA Live speakers Khaled Yamout, Sanofi’s Francoise Ribes, and Camp4’s Satya Kuchimanchi share which supply chain advancements they would like to see in the near future, as well as how they anticipate these changes & evolutions could impact each modality’s growth.

39. Transforming Nanoparticles By Continuous Manufacturing 9/13/2025

    Discover how continuous manufacturing of nanoparticles can improve process efficiency, reduce costs, and increase the quality of the final drug product.

40. Next-Generation RNA Modality Supply Considerations

    Together, Life Edit Therapeutics’ April Sena and Sanofi’s Troiano share their perspectives on raw material quality & IP-related considerations for managing the supply chain for next-generation RNA modalities.